Galderma
Galderma is an important botulinum toxin company node through two distinct relationships: aesthetic commercialization of Ipsen-origin products including Dysport in licensed territories, and the in-house development of relabotulinumtoxinA, marketed as Relfydess in multiple international markets.
Those relationships should not be collapsed. Ipsen remains central to Dysport’s product origin and therapeutic franchise, while Galderma holds significant aesthetic commercialization rights. Relfydess is a separate Galderma-developed product with its own formulation, approvals, and regulatory path.
Reference Card
Section titled “Reference Card”| Field | Reference point |
|---|---|
| Company | Galderma Group AG |
| Base | Switzerland |
| Website | galderma.com |
| Public status | SIX Swiss Exchange-listed; ticker GALD |
| Established toxin relationship | Commercialization of Dysport / Azzalure and Alluzience in licensed aesthetic markets |
| Galderma-developed toxin | RelabotulinumtoxinA, marketed as Relfydess in approved markets |
| U.S. pipeline status | FDA accepted the relabotulinumtoxinA BLA resubmission on February 2, 2026; the product remains investigational in the United States |
Dysport and Ipsen Relationship
Section titled “Dysport and Ipsen Relationship”Ipsen developed and manufactures the abobotulinumtoxinA product family. Through long-running agreements, Galderma commercializes Dysport, Azzalure, and Alluzience for aesthetic use in licensed territories, including the United States and Canada for Dysport aesthetics.
The relationship is indication- and territory-specific. It does not make Galderma the universal owner or manufacturer of every Dysport presentation, and it does not make aesthetic and therapeutic labels interchangeable.
Relfydess Development Node
Section titled “Relfydess Development Node”Galderma developed relabotulinumtoxinA internally and markets it as Relfydess in approved international markets. The company describes it as a ready-to-use liquid botulinum toxin type A product that does not require reconstitution.
By March 2026, Galderma reported Relfydess commercial activity across multiple international markets. Market authorization conditions vary by jurisdiction, so approval in Europe or another market should not be read as U.S. approval.
U.S. Regulatory Status
Section titled “U.S. Regulatory Status”On February 2, 2026, Galderma announced that the FDA had accepted its resubmitted Biologics License Application for relabotulinumtoxinA for temporary improvement of moderate-to-severe glabellar lines and lateral canthal lines in adults.
FDA acceptance of a BLA for review is not product approval. Until an approval decision is documented, relabotulinumtoxinA remains an investigational product in the United States.
Market Interpretation
Section titled “Market Interpretation”Galderma connects an established licensed franchise and a newer internally developed product. It is therefore both a commercialization node and a development node, but for different toxins. Keeping those roles separate prevents Dysport history from being attributed to Relfydess and prevents Relfydess regulatory status from being transferred to Dysport.